Phage Display

Phage Display designates a molecular technique that uses bacteriophages to present peptides or antibody fragments on their surface while encoding corresponding genetic sequences within the phage genome, enabling rapid selection of high-affinity binders to specific targets through iterative screening cycles. This platform supports discovery of therapeutic antibodies, peptide ligands, and protein interactions by linking phenotype to genotype.

The biopharmaceutical industry extensively employs phage display for antibody discovery and engineering, generating fully human antibodies that reduce immunogenicity and accelerate clinical development. Screening processes involve exposing phage libraries to immobilised targets, washing away weak binders, amplifying retained phages, and repeating cycles to enrich high-affinity candidates. Phage display enables affinity maturation by introducing mutations and selecting improved variants, optimising specificity and potency. Therapeutic antibodies discovered through phage display have achieved major clinical success across oncology, autoimmune disease, and infectious disease. Technical considerations include library diversity, target presentation ensuring native conformation, and selection stringency. As antibody formats evolve toward bispecifics and novel scaffolds, phage display remains a foundational discovery technology enabling rapid generation of clinically relevant biologics.